European urology
-
Multicenter Study Comparative Study
Retrospective comparison of triple-sequence therapies in metastatic renal cell carcinoma.
The optimal sequence of targeted therapy in patients with metastatic renal cell carcinoma (mRCC) has not been defined. ⋯ The sequence therapies VEGFi-mTORi-rTKI and VEGFi-rTKI-mTORi with the currently available agents appear to be equally efficacious in terms of PFS, OS, and response rate, with no apparent beneficial effect with an early use of mTORi.